PortfoliosLab logoPortfoliosLab logo
GRFS vs. AZN
Performance
Return for Risk
Drawdowns
Volatility
Dividends
Financials

Performance

GRFS vs. AZN - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Grifols, S.A. (GRFS) and AstraZeneca PLC (AZN). The values are adjusted to include any dividend payments, if applicable.

Loading charts...

Returns By Period

In the year-to-date period, GRFS achieves a -23.21% return, which is significantly lower than AZN's 0.51% return. Over the past 10 years, GRFS has underperformed AZN with an annualized return of -6.41%, while AZN has yielded a comparatively higher 15.87% annualized return.


GRFS

1D
-1.37%
1M
-10.03%
YTD
-23.21%
6M
-21.19%
1Y
-12.77%
3Y*
-6.49%
5Y*
-16.03%
10Y*
-6.41%

AZN

1D
2.60%
1M
-3.21%
YTD
0.51%
6M
0.29%
1Y
31.72%
3Y*
10.40%
5Y*
11.70%
10Y*
15.87%
*Multi-year figures are annualized to reflect compound growth (CAGR)

GRFS vs. AZN - Yearly Performance Comparison


2026 (YTD)202520242023202220212020201920182017
GRFS
Grifols, S.A.
-23.21%27.79%-35.64%36.00%-24.31%-37.82%-20.10%29.06%-18.28%44.48%
AZN
AstraZeneca PLC
0.51%43.30%-0.62%1.44%19.14%19.66%3.12%35.68%13.86%33.10%

Correlation

The correlation between GRFS and AZN is 0.33, which is low. Their price movements are largely independent, making them effective diversification partners.


Correlation
Correlation (1Y)
Calculated over the trailing 1-year period

0.33

Correlation (3Y)
Calculated over the trailing 3-year period

0.20

Correlation (5Y)
Calculated over the trailing 5-year period

0.20

Correlation (10Y)
Calculated over the trailing 10-year period

0.23

Correlation (All Time)
Calculated using the full available price history since Jun 2, 2011

0.26

The correlation between GRFS and AZN shifts across timeframes, from 0.20 (5 years) to 0.33 (1 year), reflecting how their relationship changes across market environments.

Fundamentals

Market Cap

GRFS:

$4.89B

AZN:

$282.57B

EPS

GRFS:

€0.61

AZN:

$6.66

PE Ratio

GRFS:

10.37

AZN:

27.19

PEG Ratio

GRFS:

0.17

AZN:

0.04

PS Ratio

GRFS:

0.58

AZN:

4.67

PB Ratio

GRFS:

0.79

AZN:

5.97

Total Revenue (TTM)

GRFS:

€7.45B

AZN:

$60.44B

Gross Profit (TTM)

GRFS:

€2.81B

AZN:

$49.37B

EBITDA (TTM)

GRFS:

€1.56B

AZN:

$20.47B

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Return for Risk

GRFS vs. AZN — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

GRFS
GRFS Risk / Return Rank: 2626
Overall Rank
GRFS Sharpe Ratio Rank: 2525
Sharpe Ratio Rank
GRFS Sortino Ratio Rank: 2323
Sortino Ratio Rank
GRFS Omega Ratio Rank: 2424
Omega Ratio Rank
GRFS Calmar Ratio Rank: 3030
Calmar Ratio Rank
GRFS Martin Ratio Rank: 2929
Martin Ratio Rank

AZN
AZN Risk / Return Rank: 7676
Overall Rank
AZN Sharpe Ratio Rank: 7878
Sharpe Ratio Rank
AZN Sortino Ratio Rank: 7777
Sortino Ratio Rank
AZN Omega Ratio Rank: 7272
Omega Ratio Rank
AZN Calmar Ratio Rank: 7575
Calmar Ratio Rank
AZN Martin Ratio Rank: 7777
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

GRFS vs. AZN - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Grifols, S.A. (GRFS) and AstraZeneca PLC (AZN). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.


GRFSAZNDifference
Sharpe ratioReturn per unit of total volatility

-1.66

Sortino ratioReturn per unit of downside risk

-2.41

Omega ratioGain probability vs. loss probability

0.96

1.23

-0.28

Calmar ratioReturn relative to maximum drawdown

-0.39

1.99

-2.38

Martin ratioReturn relative to average drawdown

-0.72

5.21

-5.93

GRFS vs. AZN - Sharpe Ratio Comparison

The current GRFS Sharpe Ratio is -0.41, which is lower than the AZN Sharpe Ratio of 1.25. The chart below compares the historical Sharpe Ratios of GRFS and AZN, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.


Loading charts...

Drawdowns

GRFS vs. AZN - Drawdown Comparison

The maximum GRFS drawdown since its inception was -78.01%, which is greater than AZN's maximum drawdown of -48.94%. Use the drawdown chart below to compare losses from any high point for GRFS and AZN.


Loading charts...

Drawdown Indicators


GRFSAZNDifference

Max Drawdown

Largest peak-to-trough decline

-78.01%

-48.94%

-29.07%

Max Drawdown (1Y)

Largest decline over 1 year

-33.15%

-16.08%

-17.07%

Max Drawdown (3Y)

Largest decline over 3 years

-52.68%

-27.87%

-24.81%

Max Drawdown (5Y)

Largest decline over 5 years

-69.29%

-27.87%

-41.42%

Max Drawdown (10Y)

Largest decline over 10 years

-78.01%

-27.87%

-50.14%

Current Drawdown

Current decline from peak

-70.65%

-13.16%

-57.49%

Average Drawdown

Average peak-to-trough decline

-31.85%

-11.37%

-20.48%

Ulcer Index

Depth and duration of drawdowns from previous peaks

17.70%

6.12%

+11.58%

Volatility

GRFS vs. AZN - Volatility Comparison

The current volatility for Grifols, S.A. (GRFS) is 6.92%, while AstraZeneca PLC (AZN) has a volatility of 7.99%. This indicates that GRFS experiences smaller price fluctuations and is considered to be less risky than AZN based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


Loading charts...

Volatility by Period


GRFSAZNDifference

Volatility (1M)

Calculated over the trailing 1-month period

6.92%

7.99%

-1.07%

Volatility (6M)

Calculated over the trailing 6-month period

24.41%

17.73%

+6.68%

Volatility (1Y)

Calculated over the trailing 1-year period

31.79%

25.60%

+6.19%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

48.78%

24.09%

+24.69%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

40.31%

24.88%

+15.43%

Dividends

GRFS vs. AZN - Dividend Comparison

GRFS's dividend yield for the trailing twelve months is around 2.45%, less than AZN's 2.94% yield.


PositionTTM20252024202320222021202020192018201720162015
AZN
AstraZeneca PLC
2.94%1.70%2.27%2.15%2.12%2.35%2.80%2.81%3.69%3.95%5.01%4.06%
GRFS
Grifols, S.A.
2.45%1.88%0.00%0.00%0.00%3.20%0.83%1.55%2.32%1.24%1.67%2.01%

Financials

GRFS vs. AZN - Financials Comparison

This section allows you to compare key financial metrics between Grifols, S.A. and AstraZeneca PLC. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


0.005.00B10.00B15.00B20222023202420252026
1.73B
15.29B
(GRFS) Total Revenue
(AZN) Total Revenue
Please note, different currencies. GRFS values in EUR, AZN values in USD

GRFS vs. AZN - Profitability Comparison

The chart below illustrates the profitability comparison between Grifols, S.A. and AstraZeneca PLC over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

Gross Margin
Operating Margin
Net Margin
Quarterly
Annual

30.0%40.0%50.0%60.0%70.0%80.0%20222023202420252026
36.5%
82.5%
Portfolio components
GRFS - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Grifols, S.A. reported a gross profit of 630.20M and revenue of 1.73B. Therefore, the gross margin over that period was 36.5%.

AZN - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, AstraZeneca PLC reported a gross profit of 12.61B and revenue of 15.29B. Therefore, the gross margin over that period was 82.5%.

GRFS - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Grifols, S.A. reported an operating income of 253.09M and revenue of 1.73B, resulting in an operating margin of 14.7%.

AZN - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, AstraZeneca PLC reported an operating income of 4.25B and revenue of 15.29B, resulting in an operating margin of 27.8%.

GRFS - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Grifols, S.A. reported a net income of 74.20M and revenue of 1.73B, resulting in a net margin of 4.3%.

AZN - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, AstraZeneca PLC reported a net income of 3.08B and revenue of 15.29B, resulting in a net margin of 20.2%.


Frequently Asked Questions


GRFS and AZN have a correlation of 0.33, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

AZN has higher volatility (7.99%) compared to GRFS (6.92%). In terms of maximum drawdown, GRFS dropped -78.01% vs AZN's -48.94%.

AZN currently has the higher Sharpe Ratio (1.25 vs -0.41), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.

Portfolio Optimizer

Find the right allocation for GRFS and AZN

Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Optimizer